Quoin Pharmaceuticals announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company’s American Depositary Shares, signaling their confidence in the company’s growth and direction. On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. These insider purchases reflect the leadership’s strong confidence in Quoin’s growth trajectory and commitment to delivering long-term value to shareholders as the company advances its mission to address unmet needs in underserved patient populations globally.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
- Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
- Quoin Pharmaceuticals reports Q2 EPS (39c), consensus (61c)
- Quoin Pharmaceuticals initiates QRX003 study
- Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome